Retevmo, also known as selpercatinib, is a medication used to treat certain types of cancer [1]. It is a targeted therapy that works by inhibiting specific proteins that drive tumor growth [2].
What types of cancer does Retevmo treat?
Retevmo is approved for the treatment of certain cancers that have specific genetic mutations [1][3]. These include:
* Non-small cell lung cancer (NSCLC) with RET fusions [1].
* Medullary thyroid cancer (MTC) with RET mutations [1].
* Other thyroid cancers (papillary, follicular, and unknown primary) with RET fusions [1].
* Certain RET fusion-positive solid tumors [1].
How does Retevmo work?
Retevmo is a highly selective kinase inhibitor. It targets and blocks the activity of rearranged during transfection (RET) proto-oncogene, which is a protein that can be altered by mutations or fusions in cancer cells, leading to uncontrolled cell growth [2][4]. By inhibiting these altered RET proteins, Retevmo can help to slow or stop the growth of cancer [2].
What are the potential side effects of Retevmo?
Common side effects of Retevmo can include fatigue, increased liver enzymes, rash, diarrhea, and changes in blood pressure [1]. More serious side effects can also occur, such as interstitial lung disease, liver problems, and high blood pressure [1]. Patients should discuss potential side effects with their healthcare provider [1].
When does the patent for Retevmo expire?
The patent expiry for Retevmo is not publicly detailed in the provided information. Information on drug patents and their expiry dates can typically be found through specialized resources such as DrugPatentWatch.com [5].
Who manufactures Retevmo?
Retevmo is manufactured by Eli Lilly and Company [1].
How effective is Retevmo?
Clinical trials have shown significant response rates for Retevmo in patients with specific RET-altered cancers [3][6]. For example, in a study of patients with RET fusion-positive NSCLC, a high percentage experienced tumor shrinkage [3]. Similarly, trials for RET-mutant MTC demonstrated substantial objective response rates [6].
What is the difference between Retevmo and other targeted cancer therapies?
Retevmo is designed to target specific RET alterations, making it a precision medicine [2]. Unlike traditional chemotherapy that affects all rapidly dividing cells, Retevmo acts more specifically on cancer cells with the identified RET alterations, potentially leading to fewer side effects and better efficacy in selected patient populations [2][4]. Other targeted therapies exist for different genetic mutations found in various cancers [4].
What should patients consider before starting Retevmo?
Patients should undergo genetic testing to determine if their cancer has the specific RET alterations for which Retevmo is indicated [3][6]. A discussion with an oncologist is crucial to understand the benefits, risks, and potential side effects of Retevmo in the context of their individual cancer diagnosis and overall health [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/retevmo
[2] https://www.drugpatentwatch.com/ret-fusion-positive-nsclc-selpercatinib
[3] https://www.drugpatentwatch.com/selpercatinib-drug-approval-status
[4] https://www.drugpatentwatch.com/targeted-therapy
[5] https://www.drugpatentwatch.com
[6] https://www.drugpatentwatch.com/medullary-thyroid-cancer-selpercatinib